{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"98.8","upperLimit":"99.6","value":"99.3"},{"groupId":"OG001","lowerLimit":"97.4","upperLimit":"98.4","value":"98.0"},{"groupId":"OG002","lowerLimit":"97.6","upperLimit":"98.6","value":"98.2"},{"groupId":"OG003","lowerLimit":"91.4","upperLimit":"94.4","value":"93.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1619"},{"groupId":"OG001","value":"3399"},{"groupId":"OG002","value":"3312"},{"groupId":"OG003","value":"1389"}],"units":"Participants"}],"description":"Distant recurrence-free interval (DRFI) is defined as time from date of randomization or registration to the date of distant recurrence of breast cancer, or of death with distant recurrence, if death is the first manifestation of distant recurrence. The distribution of DRFI (eg, 5-year DRFI rate) is estimated using Kaplan-Meier method.","dispersionType":"95% Confidence Interval","groups":[{"description":"Group 1 (Oncotype DX recurrence score =\\< 10): Patients in this group receive hormone therapy with tamoxifen, anastrozole, letrozole, or exemestane PO for up to 5 years. Some patients then continue to receive hormone therapy for an additional 5 years.\n\nAnastrozole: Given PO Exemestane: Given PO Letrozole: Given PO Tamoxifen: Given PO","id":"OG000","title":"Arm A"},{"description":"Group 2 (Oncotype DX recurrence score 11-25): Patients receive hormone therapy with tamoxifen, anastrozole, letrozole, or exemestane PO for up to 5 years. Some patients then continue to receive hormone therapy for an additional 5 years.\n\nAnastrozole: Given PO Exemestane: Given PO Letrozole: Given PO Tamoxifen: Given PO","id":"OG001","title":"Arm B"},{"description":"Group 2 (Oncotype DX recurrence score 11-25): Patients receive standard combination chemotherapy at the discretion of the treating physician. Within 4 weeks after the last dose of chemotherapy, patients receive hormonal therapy as in Group 1 at the discretion of the treating physician.\n\nAnastrozole: Given PO Exemestane: Given PO Letrozole: Given PO Tamoxifen: Given PO\n\nCombination chemotherapy: including oral CMF, IV CMF, standard AC, dose dense AC, standard AC-T, dose dense AC-T, FEC, TAC, TC, other protocol-specified regimens if participating in other CTSU trials including chemotherapy, and other regimens not protocol-specified if not participating in CTSU trials","id":"OG002","title":"Arm C"},{"description":"Group 3 (Oncotype DX recurrence score \\>= 26): Patients in this group receive combination chemotherapy followed by hormone therapy similar to the patients in Group 2 who are assigned to receive both types of treatment.\n\nAnastrozole: Given PO Exemestane: Given PO Letrozole: Given PO Tamoxifen: Given PO\n\nCombination chemotherapy: including oral CMF, IV CMF, standard AC, dose dense AC, standard AC-T, dose dense AC-T, FEC, TAC, TC, other protocol-specified regimens if participating in other CTSU trials including chemotherapy, and other regimens not protocol-specified if not participating in CTSU trials","id":"OG003","title":"Arm D"}],"paramType":"NUMBER","populationDescription":"All eligible patients who had on-study data and follow-up data","reportingStatus":"POSTED","timeFrame":"Assessed every 6 months within 5 years from registration and then annually up to 20 years, DRFI rate estimated at 5 years","title":"5-year Distant Recurrence-free Interval","type":"SECONDARY","unitOfMeasure":"percentage of participants"}